Affiliation: Karolinska Institutet
- Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohortSilvia Paddock
Genetic Basis of Mood and Anxiety Disorders, Mood and Anxiety Program, NIMH, NIH, Department of Health and Human Services, Bethesda, MD, USA
Am J Psychiatry 164:1181-8. 2007..The purpose of the present study was to utilize a second wave of genotype results, for a more powerful analysis, in the complete cohort of patients with available deoxyribonucleic acid (DNA) samples...
- Genetic markers of suicidal ideation emerging during citalopram treatment of major depressionGonzalo Laje
Genetic Basis of Mood and Anxiety Disorders, NIMH, 35 Convent Dr, Rm 1A207, Bethesda, MD 20892 3719, USA
Am J Psychiatry 164:1530-8. 2007..Genetic markers may shed light on the causes of treatment-emergent suicidal ideation and help identify individuals at high risk who may benefit from closer monitoring, alternative treatments, or specialty care...
- Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depressionXian Zhang Hu
Section on Molecular Genetics, Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA
Arch Gen Psychiatry 64:783-92. 2007....
- The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) CohortMagnus Lekman
Department of Neuroscience, Karolinska Institute, Stockholm, Sweden
Biol Psychiatry 63:1103-10. 2008..The present study aimed at studying the associated FKBP5 markers in the ethnically diverse Sequenced Treatment Alternatives to Relieve Depression (STAR*D) sample of non-hospitalized patients treated with citalopram...
- Genetic variation in GRIK4 and the implications for antidepressant treatmentSilvia Paddock
Pharmacogenomics 9:133-5. 2008